Introduction
============

Glucose variability (GV), as based on the amplitude of continuously recorded glycemic profiles, is an essential factor in the clinical control of diabetes, and high amplitudes in glucose excursions represent an independent predictor of hypoglycemia ([@B25]). Moreover, GV may be a risk factor for the development of chronic diabetes complications ([@B26]). Several indices were introduced to measure GV ([@B30]), but these classical indices only consider the amplitude of the glucose signal, i.e., the global variability, and neglect any time component ([@B19]). A few GV metrics, containing a time component are known. For example mean of daily differences ([@B24]), mean absolute glucose change ([@B13]; [@B16]), and continuous overlapping net glycemic action ([@B21]), but they firmly correlate to the amplitude-only-based indices. A new metric, glycemic variability percentage, recently introduced by [@B29], gives weight to the amplitude as well as the frequency of glucose fluctuations. However, the limitation of all these indices is that they emanate from linear analyses methods and thus fail to measure the complexity or structural variability of glucose time series. The theory of non-linear dynamics provides the basis for analysis of structural variability in complex systems ([@B33]). Consequently, variability analysis of physiological signals may either comprise evaluation by metrics from linear or non-linear methods. However, only non-linear analysis techniques provide access to the dynamics of regulatory systems.

Several researchers developed multiple measures of variability to assess the degree and patterns of physiological signal variation over time intervals in health and disease. [@B38] and [@B4] have identified several domains of variability including geometric, information, and fractal scaling domains. We selected measures of non-linear dynamics from three different variability domains proposed by [@B4]). These include Poincaré plots ([@B20]; [@B10]), multiscale entropy ([@B6]; [@B8], [@B9]), and detrended fluctuation analysis ([@B40]; [@B27]; [@B15]; [@B35]) for the variability analysis of glucose time series (**Table [1](#T1){ref-type="table"}**). These techniques have recently found application in analyzing the dynamics of glucose time series from patients with diabetes mellitus. The results of these studies collectively showed reduced dynamics of blood glucose variations in patients with diabetes as compared with non-diabetic subjects ([@B27]; [@B6]; [@B10]; [@B9]; [@B15]; [@B18]).

###### 

Techniques of variability analysis of glucose time series.

  Domain            Features                         Indices              Feature assumptions
  ----------------- -------------------------------- -------------------- -------------------------------------------------------------------------------
  Geometric         Poincaré plots features          SD1, SD2, SFE, AFE   Low dimensional representation of the dynamical attractor
  Information       Multiscale entropy               MSE                  The complexity changes depend on the window length used
  Fractal scaling   Detrended fluctuation analysis   *α1, α2*             The SD of the detrended cumulative time series has scale-invariant properties

Based on the classification of analysis techniques by

Bravi et al. (2011)

.

Beyond traditional estimates of glycemia and glycemic variability, dynamical measures may enable assessment of several extrinsic factors and treatment modalities that can modify the intrinsic dynamics of the glucoregulatory system. However, whether such factors affect glucose dynamics or which, if any, of the dynamical measures, could complement traditional clinical measures of glycemic variability in the assessment of diabetes control is not known.

Herein, we address these problems by examining glucose dynamics in type 1 and type 2 diabetes. We compare classical measures of glycemic variability with indices from different domains of variability and investigate their interrelationships. Finally, we evaluate their contribution to the quality of glycemic control and potential clinical significance.

Materials and Methods {#s1}
=====================

Study Design
------------

The present study is a cross-sectional investigation that used historical data. We conducted a retrospective analysis of ambulatory continuous glucose monitoring (CGM) profiles recorded with the second-generation MiniMed CGM system (Northridge, CA, United States) set at a sampling rate of one glucose measurement every 5 min. We analyzed the CGM data using the MiniMed Solution Software (Version 2b, Medtronic MiniMed) and utilized established measures of glucose dynamics, glycemic variability, and glycemic control. Study participants had received glucose sensors placed on their abdomen. We used a minimum of four blood glucose meter calibrations per day and a mean duration of 69-h continuous monitoring. We excluded data not meeting the validity criteria of the manufacturer (≥three paired sensor/meter readings and mean absolute difference ≤ 28%).

Study Subjects and Collection of CGM Data
-----------------------------------------

The CGM data were collected for a total of 177 study participants: Twenty-two patients with type 1 diabetes (T1D), 143 with type 2 diabetes (T2D), and 12 non-diabetic control subjects (ND). All subjects participated in the Diabetiva Program ([@B1]), an integrated national diabetes care network. The study participants entered the type and amount of food consumed into their logbooks during CGM. The entrance of consumed food enabled calculation of carbohydrate intake per day, according to standard tables containing the nutrient composition with carbohydrate exchange units ([@B23]). Of the T2D patients 42 had diet alone and of those assigned to oral therapy 63 had received common oral agents only or combinations thereof. Eighteen patients had insulin plus oral antidiabetes agents, and 20 patients received insulin alone. T1D patients (*n* = 22) had been treated with multiple daily insulin injections (MDI) of short- and long-acting insulin. A subgroup of these patients (*n* = 10) switched to continuous subcutaneous insulin injections (CSII). Patients after CSII are not included in the characteristics of the total study cohort. Eighty-five percent of all patients had taken blood pressure lowering medication. Data were not included in this evaluation if patients had severe diabetes complications or decompensated glycemic control with glycated hemoglobin (HbA1c) values \> 10% (86 mmol/mol).

The original study had obtained ethical approval and required no further approval for this retrospective data analysis.

Linear Analysis
---------------

As the primary measures of GV, we computed the percentage of coefficient of variation of glucose (%CV) and standard deviation (SD) from the data obtained and averaged the data over a 48-h CGM period ([@B31]). The glucose exposure metrics included mean glucose and glycosylated hemoglobin (HbA1c). To assess the quality of glycemic control, we computed the time (h/day) in the target range ([@B32]) and defined a range of 3.9--8.9 mmol/l as acceptable for clinical practice ([@B3]).

Non-linear Analysis
-------------------

Forty-eight hour CGM profiles obtained during recordings were used for calculation of dynamical parameters. We applied the standard Poincaré plot (PCP), which is a scattergram constructed by locating data points from the CGM time series on the coordinate plane according to the pairing *G~(t)~, G~(t)~+Δt*. *G~(t)~* is the glucose level at time *t*, and *Δt* is the time delay, which is a multiple of the sampling time of the signal. We probed *Δt* values of 30, 60, and 120 min but found *Δt* = 60 min most suitable to represent the PCP geometry characteristics for our study groups and used the code created by [@B10] to compute the pairs of coordinates defining the PCPs. *SD1* and *SD2* statistics ([@B5]), enabled quantification of the plots. The PCP measures included the minor axis of the fitting-ellipse (SD1) defined as the dispersion of data perpendicular to the line of identity and along the major axis (SD2) of the ellipse. Further PCP-derived metrics were the shape (SFE) and area (AFE) of the fitting ellipse calculated as *SFE = SD2/SD1* and *AFE = π^∗^SD1^∗^SD2* ([@B10]). Of note, although SD1 and SD2 quantify more or less linear rather than non-linear features ([@B5]; [@B34]), we formally include these indices here in differentiating them from traditional measures of global GV.

The analysis of multiscale entropy (MSE) for the CGM sequences utilized the previously described procedure ([@B6]; [@B9]). This procedure comprised: (1) derivation of a set of time series from the original glucose signal on different time scales using the coarse-graining technique, (2) computation of sample entropy (SampEn) with standard parameter values for each coarse-grained time series. We chose the window length *m* = 2, the sensitivity criterion *r* = 0.15 times the SD, and the data length *N* = 576 within the entire coarse-grained sequence with the broadest scale factor set at *M* = 5. Thus, the length of the coarse-grained data ([@B14]) at this scale factor contained 115 glucose samples. We calculated SampEn for the scales 1 to 5, using the mse.c program available at <https://www.physionet.org/physiotools/mse/tutorial/>.

The complexity index was defined as the sum of these SampEn values.

We also analyzed the CGM time series by calculating the detrended fluctuation analysis (DFA) according to the standard method, as described by ([@B40]), which involves the integration of the time series and dividing it into intervals of equal size *n*. Integration of the time series was performed as follows:
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*F(n)* is the calculated detrended fluctuation represented as the root-mean-square fluctuation from the trend summed up for all boxes (*B*) with *B(i)* as each point in the time series and *B~ave~* as the average of the whole series.
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1.  *n:* size of the time segments (windows) of the integrated curve

2.  *F(n):* the measure of the difference between the integrated curve and the regression lines

3.  *y(k)*: the value at each individual point of the integrated curve

4.  *y~n~(k)*: the value of the regression line at the point

5.  *N*: the total number of data points

Plots drawn with *log F(n)* on the y-axis and *log(time window)* permitted computation of the α exponents and constructing the slope of the line relating *F(n)* to *log(time window).* Because of the crossover phenomenon observed in the regression line *α* ([@B28]), we split the regression line into two regions, the short-term (*α1*) and long-term (*α2*) range. Alpha 1 represents the slope of the regression within 1.25 h calculated as *n* = 2--16 points and *α2* the slope of the regression over 1.25 h from 16 to 144 data points.

Statistical Analysis
--------------------

We categorized the patients into type 1 and type 2 diabetes and included a control group of healthy participants. We used one-way analysis of variance (ANOVA) and the *t*-test with Bonferroni--Holm correction for control of multiple pairwise comparisons. The two-tailed paired Student's *t*-test permitted comparison between MDI and CSII data. Variables are presented as means ± SD and their statistical significance by a two-tailed test. Diabetes duration is given as median (25th -- 75th) percentile. Spearman's correlation revealed the strength of associations between dynamical indices and linear regression analyses and their associations with conventional GV measures. Multiple linear regression analysis used a core model (standardized regression coefficient denoted by *β*) that consisted of the following covariates: age, sex, diabetes duration, body mass index, carbohydrate intake, and antidiabetic therapy (CORE MODEL). Antidiabetic therapy was coded: 1 = none, 2 = diet with/without oral agents, 3 = oral agents with/without insulin and 4 = insulin alone. Stepwise forward selection identified confounding variables ([@B22]). The variance inflation factor (VIF) and Durbin-Watson statistic ensured the absence of confounding effects. Results at *p* \< 0.05 were statistically significant. We applied the Statistical Package for the Social Sciences software package (version 17.0; SPSS, Chicago, IL, United States) for statistical analyses.

Results
=======

Characteristics of Study Subjects
---------------------------------

The summary of demographic and clinical characteristics of the study cohort in **Table [2](#T2){ref-type="table"}** shows that patients with T2D were significantly older (65.4 ± 8.2 years) than those with T1D (43.3 ± 15.2 years) or the ND control subjects (44.3 ± 12.4 years), but the age difference between the T1D and ND group was not statistically significant. Diabetes duration (years) was shorter in T2D \[7.0 (3.0 -- 12.0)\] than in T1D \[20.5 (14.8 -- 29.0)\], and body mass index was higher in T2D than in T1D patients (30.3 ± 4.8 vs. 25.3 ± 3.9 kg/m^2^). However, carbohydrate intake and hemoglobin A1c (HbA1c %) were lower in T2D patients than in patients with T1D; HbA1c (6.8 ± 1.0 vs. 7.7 ± 0.9), whereas mean glucose levels did not significantly differ (*p =* 0.37) between these two diabetes groups. As expected, the global GV measured by %CV was markedly higher (*p \<* 0.001) in the group of T1D patients than in the T2D (36.9 ± 8.6 vs. 20.2 ± 7.4) and ND (15.7 ± 3.5) groups. Likewise, SD was significantly higher in the T1D than in the T2D and ND group. Consistent with the data on glucose exposure and GV, the time spent in target range was significantly longer (*p* \< 0.001) in the ND than in the T2D and T1D group (23.4 ± 1.0 vs. 17.4 ± 6.2 vs. 13.2 ± 3.8).

###### 

Demographic and metabolic characteristics of diabetic patients and control subjects.

  Characteristic                    Type 1 Diabetes       Type 2 Diabetes        Non-diabetes   *P*- value
  --------------------------------- --------------------- ---------------------- -------------- ------------
  Patients (*n*)                    22                    143                    12             
  Sex (male/female)                 11/11                 91/52                  5/7            
  Age (years)                       43.3 ± 15.2           65.4 ± 8.2^∗∗∗,+++^    44.3 ± 12.4    \<0.001
  Diabetes duration (years)         20.5 (14.8 -- 29.0)   7.0 (3.0 -- 12.0)^∗^   NA             \<0.001
  Body mass index (kg/m^2^)         25.3 ± 3.9            30.3 ± 4.8^∗∗∗^        27.1 ± 4.1     \<0.001
  Carbohydrate intake (g/day)       211.8 ± 46.6          138.8 ± 50.7^∗∗,+++^   185.6 ± 35.3   \<0.001
  **Glucose exposure**                                                                          
  Hemoglobin A1C (%)                7.7 ± 0.9^+++^        6.8 ± 1.0^∗∗∗,+++^     5.0 ± 0.3      \< 0.001
  Hemoglobin A1C (mmol/mol)         61                    51                     31             
  Mean glucose (mmol/l)             8.0 ± 1.7^+++^        7.8 ± 2.0^+++^         5.4 ± 0.5      \<0.001
  **Glucose variability**                                                                       
  Coefficient of variation (%)      36.9 ± 8.6^+++^       20.2 ± 7.4^∗∗∗^,^+^    15.7 ± 3.5     \<0.001
  Standard deviation (mmol/l)       2.9 ± 0.7^+++^        1.6 ± 0.7^∗∗∗,+++^     0.9 ± 0.2      \<0.001
  **Quality of glycemic control**                                                               
  Time in target range (h/day)      13.2 ± 3.8^+^         17.4 ± 6.2^∗,+^        23.4 ± 1.0     \<0.001

Data are mean ± SD or median (25th -- 75th percentile) values. (NA), not applicable. The groups were compared using analysis of variance (ANOVA) and
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The Dynamics of CGM Tracings in the Study Groups
------------------------------------------------

Comparison of sample CGM tracings (**Figure [1](#F1){ref-type="fig"}**) obtained from a non-diabetic control subject (**Figure [1A](#F1){ref-type="fig"}**) a patient with T2D (**Figure [1B](#F1){ref-type="fig"}**), and T1D patient (**Figure [1C](#F1){ref-type="fig"}**) exemplified that the selected dynamical indices are capable of expressing differences in glucose dynamics between individual patients. Despite well-controlled diabetes, as reflected by HbA1c \< 7.0% and mean glucose values \< 9.4 mmol/l, significant glycemic fluctuations in the CGM time series were evident in the two diabetic patients. There SD2, AFE, *α* exponents increased, and MSE values decreased, indicating altered glucose dynamics as compared with that of the non-diabetic sample. Note, high PCP metrics and low MSE index values correlated with large glycemic fluctuations and loss of the information content of the glucose signal.

![Analysis of samples of 48-h continuous glucose monitoring tracings obtained from **(A)** a non-diabetic control subject (ND), **(B)** a patient with type 2 diabetes (T2D) on sulfonylurea treatment, and **(C)** a type 1 diabetic (T1D) patient treated with multiple insulin injections. The columns (from left to right) show the CGM profiles, detrended fluctuation analysis, and Poincaré plots. The glycemic characteristics and the dynamical indices derived from the glucose time series are shown in **Table [6](#T6){ref-type="table"}**. Note the increase in the Poincaré indices SD1, SD2, and AFE, the decrease in MSE as well as the increasing short- (*α1*) and long-term (*α2*) fractal scaling exponent when moving from the non-diabetic subject down to the T1D patient.](fphys-09-01257-g001){#F1}

Dynamical Indices in Diabetic Patients and Non-diabetic Control Subjects
------------------------------------------------------------------------

**Figure [2](#F2){ref-type="fig"}** shows that the selected non-linear GV indices in diabetic patients are significantly different (*p* \< 0.05) from those in non-diabetic subjects (ND). Moreover, except for SFE, all other metrics of PCP geometry were higher in T1D than in patients with T2D (**Figures [2A,B](#F2){ref-type="fig"}**). The SFE index did not differ between the T1D and T2D group 2.51 ± 0.58 vs. 2.26 ± 0.64, *p* = 0.08). On the contrary, the MSE index values (**Figure [2C](#F2){ref-type="fig"}**) increased significantly (*p* \< 0.001) between groups when moving from T1D (3.29 ± 0.83) to T2D (3.89 ± 1.19) and finally to the ND group (5.31 ± 1.10). Lower MSE indices correlated with higher %CV values (-0.313, *p* \< 0.001). These changes indicate a loss of complexity in the glucose time series of diabetic patients. The two DFA *α* exponents in **Figure [2D](#F2){ref-type="fig"}** were higher in diabetes compared to non-diabetes, but among both diabetes groups, were higher in patients with T1D than in those with T2D: *α1* (1.95 ± 0.12 vs. 1.75 ± 0.12, *p* \< 0.001) and *α2* (1.38 ± 0.11 vs. 1.30 ± 0.15, *p* = 0.017).

![Comparison of glucose variability indices in non-diabetes (ND), type 2 (T2D), and type 1 diabetes (TD1) from the geometric, information, and fractal scaling domains. Analysis of variance (*ANOVA*) and *t*-test with Bonferroni--Holm correction gave the between-group differences as indicated: ^∗^*p* \< 0.05, ^∗∗∗^*p* \< 0.001 vs. type 2 diabetes and ^++^*p* \< 0.01, ^+++^*p* \< 0.001 vs. non-diabetes.](fphys-09-01257-g002){#F2}

Correlations Among Indices From Different Variability Domains
-------------------------------------------------------------

When we investigated the associations between the classical PCP indices by Spearman's correlation analysis (**Table [3](#T3){ref-type="table"}**), we found strong correlations of SD1 and SD2 with the AFE index (*r* = 0.776--0.805, *p* \< 0.001 for all). We noticed weak negative associations between SD1 and SFE (*r* = -0.167, *p* = 0.026), whereas those with SD2 (0.604, *p* \< 0.001 were stronger. The associations among MSE and the PCP indices were moderate but inverse for SD1, SD2, SFE, and AFE, (*r =* -0.432 to -0.564, *p* \< 0.001), and with the exponent *α1* (*r* = -0.401, *p* \< 0.001) and *α2* (*r =* -0.385, *p* \< 0.001).

###### 

Spearman correlation coefficients among measures of glucose dynamics.

                                   Poincaré plot      Multiscale   Detrended fluctuation                                                  
  -------------------------------- ------------------ ------------ ----------------------- ------------ ------------ ------------ ------- ---
  Poincaré plot                    SD1 (short term)   1                                                                                   
                                   SD2 (long term)    **0.872**    1                                                                      
                                   SFE (shape)        -0.167       **0.604**               1                                              
                                   AFE (area)         **0.776**    **0.805**               **0.365**    1                                 
  Multiscale entropy               MSE                **-0.432**   **-0.549**              **-0.437**   **-0.564**   1                    
  Detrended fluctuation analysis   α1 (short term)    **0.468**    **0.454**               0.160        **0.489**    **-0.401**   1       
                                   α2 (long term)     0.270        **0.600**               **0.780**    **0.433**    **-0.385**   0.236   1

Correlations at the significance level of

p

\< 0.001 are given in bold face; those at

p

\< 0.05 (two-tailed) in regular type face

.

Relationships Between Dynamical Indices and Conventional Measures of Global Glucose Variability
-----------------------------------------------------------------------------------------------

Linear regression analysis of dynamical variables against conventional metrics of glycemic variability (**Table [4](#T4){ref-type="table"}**) indicated that the PCP descriptors SD1, SD2, and AFE, with the exception of SFE, have a consistently closer and positive relationship with %CV (*β =* 0.78--0.82, *p \<* 0.001) than the DFA α exponents (*β* = 0.47 and 0.41, *p* \< 0.001). In contrast, the complexity index, MSE, has a weak, negative relationship (*β* = -0.36 and -0.38, *p* \< 0.001) with %CV and SD. These results clearly show that numerically higher PCP metrics and DFA exponents relate to larger glucose fluctuations, whereas lower complexity index values correlate with higher glycemic variability.

###### 

Linear regression analysis of indices of glucose dynamics against conventional measures of glycemic variability Coefficient of Variation (%CV) and Standard deviation (SD).

                         %CV   *SD*                                    
  ---------------------- ----- ------- ------ --------- ------- ------ ----------
  Poincaré plot          SD1   0.82    0.67   \<0.001   0.90    0.81   \<0.001
                         SD2   0.82    0.67   \<0.001   0.94    0.88   \<0.001
                         SFE   -0.34   0.11   \<0.001   -0.44   0.19   \<0.001
                         AFE   0.78    0.60   \<0.001   0.86    0.74   \<0.001
  Multiscale entropy     MSE   -0.36   0.13   \<0.001   -0.38   0.14   \<0.001
  Detrended              α1    0.47    0.22   \<0.001   0.43    0.14   \<0.001
  fluctuation analysis   α2    0.41    0.16   \<0.001   0.47    0.22   \< 0.001

Dynamical Indices as Determinants of the Quality of Glucose Control
-------------------------------------------------------------------

We performed multiple regression analyses to assess the independent effects of glucose dynamics on TIR as the quality measure of glycemic control. We included %CV as the conventional, linear measure of GV and the covariates age, sex diabetes duration, body mass index, carbohydrate intake, and antidiabetic therapy (**Supplementary Table [1](#SM1){ref-type="supplementary-material"}**, see link on this article). In the fully adjusted regression models (model 2--5, 8) the dynamical indices were associated with TIR. Out of these, models 2, 3, and 5 achieved an adjusted *R^2^* of 0.39, 0.50, and 0.31 with SD1 (*β* = -0.78), SD2 (*β* = -1.00), and AFE (*β* = -0.58); %CV *β* = 0.34, 0.47, and 0.11, respectively. The statistical significance for SD1, SD2, and AFE was *p* \< 0.001. These regression analyses revealed that SD1, SD2, and AFE were the most powerful predictor variables of the quality of glycemic control presented as TIR. SFE (*β =* -0.29) and *α2* (*β =* -0.32) were also significant (both *p* \< 0.001) but weaker predictors. The covariates age, sex, diabetes duration, body mass index, carbohydrate intake, and antidiabetic therapy, except for carbohydrate intake in model 4 and 8, failed to contribute significantly. MSE (model 6) was not a significant predictor. In the regression models integrating the variables AFE, SFE, and *α2*, %CV failed to contribute to TIR. The variance inflation factors (≤3.5) and the Durban-Watson statistic (1.8 -- 2.1) confirmed the absence of significant collinearity.

Glucose Dynamics Before and After Switching From Multiple Daily Insulin Injections to Continuous Subcutaneous Insulin Infusions
-------------------------------------------------------------------------------------------------------------------------------

The transition from multiple daily insulin injections (MDI) to continuous subcutaneous insulin infusions (CSII) in a subgroup of 10 patients with T1D, reduced SD1, SD2, and the AFE index except for SFE (**Table [5](#T5){ref-type="table"}**). The significant reduction by roughly 50% in SD1, SD2, and AFE indicates an overall improvement in PCP geometry. Whereas the MSE index decreased (3.09 ± 0.94 vs. 1.93 ± 0.40, *p* = 0.001), the DFA scaling exponents *α1* (2.04 ± 0.06 vs. 2.09 ± 0.02, *p* = 0.05) and *α2* (1.43 ± 0.11 vs. 1.57 ± 0.36, *p* = 0.16) did not significantly vary. These latter results suggest a further loss of complexity and a non-significant change in fractal-like behavior of the glucose time series after initiation of insulin pump therapy. HbA1c (range 7.3 -- 10.3% at baseline) and the mean glucose levels (range 6.2 -- 12.1 mmol/l at baseline) did not significantly change. As **Table [5](#T5){ref-type="table"}** further shows, the amplitude-based glucose fluctuations, measured as %CV and SD, declined markedly (*p* = 0.003 and 0.010, respectively). Likewise, the quality of diabetes control ameliorated, as TIR increased from 13.0 to 17.7 h/day (*p* = 0.021). This result is consistent with the CGM profiles in **Figure [3](#F3){ref-type="fig"}**, demonstrating lower glycemic amplitudes and better glycemic control after the commencement of CSII therapy (**Figure [3B](#F3){ref-type="fig"}**).

###### 

Comparison of dynamic and glycemic measures in type 1 diabetic patients before and after initiation of continuous subcutaneous insulin infusion therapy.

                          Before CSII    At 6 months after   *P*-value
  ----------------------- -------------- ------------------- -----------
  **Dynamic measures**                                       
  SD1 (mmol/l)            1.66 ± 0.37    0.81 ± 0.19         \<0.001
  SD2 (mmol/l)            4.37 ± 0.74    2.47 ± 0.90         \<0.001
  SFE                     2.75 ± 0.74    3.07 ± 0.86         0.17
  AFE (mmol^2^/l^2^)      23.07 ± 7.18   6.48 ± 3.32         \<0.001
  MSE                     3.09 ± 0.94    1.93 ± 0.40         0.001
  *α1*                    2.04 ± 0.06    2.09 ± 0.02         0.05
  *α2*                    1.43 ± 0.11    1.57 ± 0.36         0.16
  **Glycemic measures**                                      
  HbA1c (%)               8.2 ± 0.85     7.7 ± 0.51          0.07
  Mean glucose (mmol/l)   7.4 ± 1.2      7.5 ± 1.6           0.83
  CV (%)                  39.9 ± 8.5     24.3 ± 6.8          0.003
  SD (mmol/l)             2.9 ± 0.6      1.8 ± 0.7           0.010
  Time in range (h/day)   13.0 ± 3.0     17.7 ± 5.3          0.021

The number of patients was

n

= 10. Data are mean ± SD values.

P

-values are two-tailed

.

###### 

Summary of characteristics and metrics of the continuous glucose monitoring profiles shown in **Figure [1](#F1){ref-type="fig"}** for a non-diabetic control subject (ND), a patient with type 2 diabetes (T2D), and a type 1 diabetic patient (T1D).

  ID       Group   Diabetes duration   HbA1c (%)   Mean glucose   CV (%)   SD1    SD2    AFE     MSE    α1     α2
  -------- ------- ------------------- ----------- -------------- -------- ------ ------ ------- ------ ------ ------
  777773   ND      NA                  5.1         5.6            23.42    0.81   2.00   5.08    5.47   1.81   1.32
  128701   T2D     13                  6.1         6.1            26.27    1.11   2.39   8.31    4.66   1.83   1.24
  125264   T1D     29                  6.8         8.7            32.37    1.48   3.67   17.06   2.86   2.02   1.53

![Continuous glucose monitoring tracings obtained from patients (*n* = 10) with type 1 diabetes **(A)** before and **(B)** 6 months after initiation of insulin pump therapy. Tracings are shown for each patient with the average curve in bold. The corresponding dynamic and glycemic measures are shown in **Table [5](#T5){ref-type="table"}**.](fphys-09-01257-g003){#F3}

Discussion
==========

Glucose time series may differ in individual diabetic patients despite comparable HbA1c and mean glucose levels because such clinical, linear measures are not appropriate to reveal the inherent dynamics of the glucoregulatory system.

We demonstrate that several indices derived from the geometric, information, and fractal scaling domains of variability techniques can characterize the variability of glucose time series in health and diabetes. Previous studies in the literature ([@B40]; [@B15]; [@B6]; [@B9]; [@B39]), using various non-linear signal processing techniques, reported that glucose dynamics appears reduced in patients with diabetes compared with non-diabetic subjects. However, it is not known whether the type and severity of diabetes or factors such as age, diabetes duration, BMI, and carbohydrate intake or antihyperglycemic therapy may affect the dynamical behavior of glucose time series. Regarding the natural history of diabetes, immune-mediated destruction of the pancreatic β-cells leading to an irreversible loss of the β-cell mass characterizes T1D, whereas in T2D a progressive decline of β-cell function over time occurs with rising insulin resistance and deterioration of glucose regulation. Because of the diverse pathogenic mechanisms, T1D needs insulin and is difficult to control, but those patients with T2D are able to manage their disease mostly with a variety of oral antihyperglycemic agents.

The indices derived from PCP and DFA analysis in the present study provided qualitatively similar results with respect to the differentiation of the glucose time series dynamics between the two types of diabetes, i.e., the values for these indices be significantly lower in the T2D than in the T1D group but were lowest in the ND group. In contrast, the complexity index calculated from MSE is highest in the ND group and lowest in the T1D group. These data are also compatible with the increase in glucose fluctuations (reduced non-linear autocorrelation) and thus with the diminished glycemic stability observed in the glucose profile structure of our T1D and T2D patient samples (**Figure [1](#F1){ref-type="fig"}**). In so far PCP descriptors in T1D and healthy control subjects are concerned, this is in agreement with a report by [@B10]. Regarding the ratio of long-term to short-term glucose time series variability, SFE was correspondingly higher in patients with T1D than in the non-diabetic subjects. Numerically high PCP indices unequivocally point toward dynamical instability in the glucoregulation. Nevertheless, the indices SD1, SD2, and AFE of PCP analysis quantify linear rather than non-linear features of the underlying time series ([@B5]; [@B11]). Consistent with the changes that occurred in the PCP geometry, the decreased MSE, and the altered DFA plots with increased *α1* and α2 exponents observed in the T1D group further indicate significant alterations in the feedback mechanism that is less able to diminish glucose fluctuations in patients with T1D than in those with T2D.

Our previous results demonstrated that the β-cell function is an independent predictor of glucose time series dynamics as measured by the DFA alpha exponents ([@B17]). Thus, the reduced glucose dynamics in the T1D versus the T2D patient group allows the assumption that worsening of the glucoregulation is partly due to the loss of the β-cell secretory capacity, whereas the remaining β-cell reserve prevents such derailment in T2D. The variability indices from the different domains correlated weakly or moderately to one another. As one could expect, the strongest correlations existed between the PCP indices within the geometric domain. The unexpectedly weak correlation across the variability domains suggests that the indices are not interchangeable. These correlations are in a way comparable with those found for the cardiac interbeat time series ([@B2]) because the information retrieved from PCP and from DFA analysis show structural correlations of the underlying dynamics. By the multivariate regression analyses, we disclosed that the measures of glucose profile dynamics are independent predictors of the quality of glucose control, as defined by the time spent in target range (TIR). The analyses showed that the PCP indices SD1, SD2, and AFE along with %CV were independent determinants of TIR (**Supplementary Table [1](#SM1){ref-type="supplementary-material"}**). Sex, age, diabetes duration, BMI, carbohydrate intake, and antidiabetic treatment had, if any, no substantial influence. Of note, we found that SD1, SD2, and AFE explained 35, 44, and 29%, respectively, of the interindividual variance in TIR compared to an additional 3--8% defined by the %CV. The variables SFE and *α2*, even significant in the regression models, were weaker predictors, explaining 17 and 21% of TIR. Moreover, the regression models (4, 5, and 8) including SFE, AFE, and *α2* demonstrate that these measures predicted the quality of glycemic control, whereas the overall glycemic variability as measured by %CV was not a significant predictor. The MSE did not determine TIR which indicates that this index is not useful in the assessment of the quality of glycemic control. Therefore, the evaluated indices do not reflect purely the global GV, although they relate to conventional measures of GV. Methods analyzing the fluctuation of glucose time series are not detecting the same phenomena as those methods that identify amplitude-based glycemic variability. Indeed, a loss in glucose time series dynamics gives rise to increased overall glycemic variability ([@B12]). Although strongly correlated with SD (in our study *r* = 0.876, *p* \< 0.0001), we chose %CV for our regression models as the standard metric of GV in clinical research ([@B32]) to compare its effect on TIR with those indices from the different variability domains. We used TIR as an established and clinically useful indicator of the quality of glycemic control, reflecting the time in predefined target ranges ([@B3] and [@B32]).

Finally, we investigated the dynamics of glucose time series in a cohort of T1D patients in response to insulin pump therapy. CSII yielded a marked improvement in the PCP geometry--consistent with the report by [@B10], except for the SFE descriptor, with a corresponding decrease in glycemic variability (calculated as %CV and SD) and increased quality of glycemic control as evaluated using TIR. Although HbA1c did not significantly change and mean glucose not markedly drop ([@B37]), one may conclude that overall glycemia improved because of reduced glycemic variability and increased TIR. Of note, however, the MSE index decreased, whereas the DFA long-term exponent *α2* tended to increase. This is an unexpected result, and we do not have any plausible explanation, because healthier glycemic dynamics are associated both with higher MSE values and lower α exponents (see **Figures [2C,D](#F2){ref-type="fig"}**). Nevertheless, these finding suggests that even 6 months of CSII could not halt the loss of glucose time series complexity and fractal structure in glucose dynamics. In other words, CSII therapy is inappropriate to reverse glucose dynamics to those of non-diabetic subjects. We assume that owing to the absolute β-cell insulin deficiency in T1D, the glucoregulatory system remains insufficient to correct defective glucose dynamics. Islet transplantation rather than insulin pump therapy would offer restoration of the β-cell function ([@B36]). Whether such therapy can restore glucose complexity and the fractal structure is not known and requires appropriate clinical studies.

This study has limitations in as much as it is retrospective in nature, and the number of subjects in the T1D and ND group is relatively small. Furthermore, the follow-up time in the patients after insulin pump therapy appears too short to allow restitution of glucose complexity and the fractal structure of glucose time series. In patients with T2D, for example, β-cell function began to increase not until after 12 months of CSII therapy ([@B7]). The strength of the investigation is the use of indices from different variability domains and classical GV measures as well as the inclusion of both patients with T1D and T2D to enable comparison of glucose dynamics between distinct types of diabetes.

In summary, this study provides evidence that glucose time series dynamics differ between the two primary forms of diabetes. The loss of complexity is more pronounced in T1D than in T2D, which we anticipate is due to differences in the β-cell pathology. Insulin pump therapy for 6 months can not reverse multiscale dynamics toward those of non-diabetic subjects because of the failure to mimic healthy patterns of insulinemia. Our findings, which corroborate and extend previous work by others, also emphasize the need for using an ensemble of indices from various variability domains to characterize glucose time series more specifically. Moreover, we show that a combination of several dynamical metrics and classical GV measures has the potential to assess both the natural glucoregulatory system and quality of blood glucose control which may help in approaching diabetes treatment on a personalized basis.
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